XBI holdings - what the fund actually owns
State Street(R) SPDR(R) S&P(R) Biotech ETF reports 149 stock positions to the SEC, 100% of its assets. The ten largest are 13.3% of the fund, as of Jun 30, 2026.
Each week Ploutos reads the latest N-PORT filing of the largest US equity ETFs. This page is one fund's filing: its reported positions with their weights, where that weight sits by sector, what entered and left since the previous filing, and which other funds hold the most of the same stocks.
Reported positions
149
cover 100% of the fund
Weight of the top 10 holdings
13.3%
of the fund in ten names
Largest position
APOGEE THERAPEUTICS INC
1.49% · Apogee Therapeutics Inc
Filing date
Jun 30, 2026
holdings as reported to the SEC
Where the weight sits, by sector
Sectors come from each company's industry code in its SEC record, so they are coarse. 2.4% of the reported weight could not be placed and is shown as unknown.
Full holdings list, heaviest first
| # | Stock | Weight | Cumulative |
|---|---|---|---|
| 1 | APOGEE THERAPEUTICS INC | 1.49% | 1.5% |
| 2 | MRNAModerna Inc | 1.41% | 2.9% |
| 3 | TWSTTwist Bioscience Corp | 1.41% | 4.3% |
| 4 | ORKAOruka Therapeutics Inc | 1.38% | 5.7% |
| 5 | KYMRKymera Therapeutics Inc | 1.36% | 7.0% |
| 6 | VKTXViking Therapeutics Inc | 1.30% | 8.4% |
| 7 | PRAXPraxis Precision Medicines Inc | 1.29% | 9.6% |
| 8 | ERASErasca Inc | 1.27% | 10.9% |
| 9 | RVMDRevolution Medicines Inc | 1.20% | 12.1% |
| 10 | RYTMRhythm Pharmaceuticals Inc | 1.20% | 13.3% |
| 11 | CGONCG oncology Inc | 1.20% | 14.5% |
| 12 | SLSSELLAS Life Sciences Group Inc | 1.19% | 15.7% |
| 13 | PCVXVaxcyte Inc | 1.19% | 16.9% |
| 14 | DNTHDianthus Therapeutics Inc | 1.18% | 18.1% |
| 15 | CYTKCytokinetics Inc | 1.18% | 19.3% |
| 16 | NTRANatera Inc | 1.16% | 20.4% |
| 17 | SRRKScholar Rock Holding Corp | 1.16% | 21.6% |
| 18 | ROIVRoivant Sciences Ltd | 1.16% | 22.7% |
| 19 | MIRMMirum Pharmaceuticals Inc | 1.16% | 23.9% |
| 20 | COGTCogent Biosciences Inc | 1.14% | 25.0% |
| 21 | RAREUltragenyx Pharmaceutical Inc | 1.14% | 26.2% |
| 22 | TVTXTravere Therapeutics Inc | 1.13% | 27.3% |
| 23 | ALKSAlkermes PLC | 1.11% | 28.4% |
| 24 | KRYSKrystal Biotech Inc | 1.10% | 29.5% |
| 25 | CELCCelcuity Inc | 1.10% | 30.6% |
| 26 | RLAYRelay Therapeutics Inc | 1.10% | 31.7% |
| 27 | SYRESpyre Therapeutics Inc | 1.10% | 32.8% |
| 28 | TGTXTG Therapeutics Inc | 1.09% | 33.9% |
| 29 | BEAMBeam Therapeutics Inc | 1.08% | 35.0% |
| 30 | INSMInsmed Inc | 1.08% | 36.1% |
| 31 | PTGXProtagonist Therapeutics Inc | 1.07% | 37.1% |
| 32 | ARWRArrowhead Pharmaceuticals Inc | 1.07% | 38.2% |
| 33 | VERAVera Therapeutics Inc | 1.06% | 39.3% |
| 34 | VRTXVertex Pharmaceuticals Inc | 1.06% | 40.3% |
| 35 | MDGLMadrigal Pharmaceuticals Inc | 1.06% | 41.4% |
| 36 | ABBVAbbVie Inc | 1.04% | 42.4% |
| 37 | BIIBBiogen Inc | 1.03% | 43.4% |
| 38 | PTCTPTC Therapeutics Inc | 1.03% | 44.5% |
| 39 | HALOHalozyme Therapeutics Inc | 1.03% | 45.5% |
| 40 | QUREuniQure NV | 1.03% | 46.5% |
| 41 | BBIOBridgebio Pharma Inc | 1.02% | 47.6% |
| 42 | CRSPCRISPR Therapeutics AG | 1.02% | 48.6% |
| 43 | IBRXImmunityBio Inc | 1.02% | 49.6% |
| 44 | SMMTSummit Therapeutics Inc | 1.01% | 50.6% |
| 45 | IONSIonis Pharmaceuticals Inc | 1.00% | 51.6% |
| 46 | INCYIncyte Corp | 1.00% | 52.6% |
| 47 | AMGNAmgen Inc | 0.99% | 53.6% |
| 48 | NBIXNeurocrine Biosciences Inc | 0.97% | 54.6% |
| 49 | GILDGilead Sciences Inc | 0.96% | 55.5% |
| 50 | REGNRegeneron Pharmaceuticals Inc | 0.96% | 56.5% |
| 51 | EXELExelixis Inc | 0.96% | 57.5% |
| 52 | ALNYAlnylam Pharmaceuticals Inc | 0.96% | 58.4% |
| 53 | BMRNBioMarin Pharmaceutical Inc | 0.94% | 59.4% |
| 54 | ACADACADIA Pharmaceuticals Inc | 0.94% | 60.3% |
| 55 | NUNuvalent Inc | 0.93% | 61.2% |
| 56 | IMVTImmunovant Inc | 0.92% | 62.2% |
| 57 | UTHRUnited Therapeutics Corp | 0.92% | 63.1% |
| 58 | NTLAIntellia Therapeutics Inc | 0.91% | 64.0% |
| 59 | GRALGRAIL Inc | 0.91% | 64.9% |
| 60 | BCRXBioCryst Pharmaceuticals Inc | 0.89% | 65.8% |
| 61 | CATALYST PHARMACEUTICALS INC | 0.87% | 66.7% |
| 62 | DYNDyne Therapeutics Inc | 0.86% | 67.5% |
| 63 | TNGXTango Therapeutics Inc | 0.84% | 68.4% |
| 64 | DNLIDenali Therapeutics Inc | 0.83% | 69.2% |
| 65 | VCYTVeracyte Inc | 0.82% | 70.0% |
| 66 | IDYAIdeaya Biosciences Inc | 0.80% | 70.8% |
| 67 | RXRXRecursion Pharmaceuticals Inc | 0.76% | 71.6% |
| 68 | SRPTSarepta Therapeutics Inc | 0.75% | 72.3% |
| 69 | RCUSArcus Biosciences Inc | 0.74% | 73.1% |
| 70 | SNDXSyndax Pharmaceuticals Inc | 0.72% | 73.8% |
| 71 | ARQTArcutis Biotherapeutics Inc | 0.71% | 74.5% |
| 72 | MLYSMineralys Therapeutics Inc | 0.71% | 75.2% |
| 73 | CLDXCelldex Therapeutics Inc | 0.70% | 75.9% |
| 74 | AGIOAgios Pharmaceuticals Inc | 0.69% | 76.6% |
| 75 | VRDNViridian Therapeutics Inc | 0.67% | 77.3% |
| 76 | NVAXNovavax Inc | 0.66% | 77.9% |
| 77 | IRONDisc Medicine Inc | 0.65% | 78.6% |
| 78 | ADMAADMA Biologics Inc | 0.61% | 79.2% |
| 79 | IMNMImmunome Inc | 0.59% | 79.8% |
| 80 | PVLAPalvella Therapeutics Inc | 0.58% | 80.4% |
| 81 | IOVAIovance Biotherapeutics Inc | 0.56% | 80.9% |
| 82 | ABSIAbsci Corp | 0.56% | 81.5% |
| 83 | NRIXNurix Therapeutics Inc | 0.56% | 82.0% |
| 84 | KODKodiak Sciences Inc | 0.54% | 82.6% |
| 85 | BHVNBiohaven Ltd | 0.53% | 83.1% |
| 86 | VCELVericel Corp | 0.50% | 83.6% |
| 87 | ANABAnaptysBio Inc | 0.49% | 84.1% |
| 88 | CAPRCapricor Therapeutics Inc | 0.49% | 84.6% |
| 89 | STOKStoke Therapeutics Inc | 0.48% | 85.1% |
| 90 | GLUEMonte Rosa Therapeutics Inc | 0.48% | 85.5% |
| 91 | VIRVir Biotechnology Inc | 0.47% | 86.0% |
| 92 | PURRHyperliquid Strategies Inc | 0.46% | 86.5% |
| 93 | TYRATyra Biosciences Inc | 0.41% | 86.9% |
| 94 | CRVSCorvus Pharmaceuticals Inc | 0.41% | 87.3% |
| 95 | CGEMCullinan Therapeutics Inc | 0.40% | 87.7% |
| 96 | PGENPrecigen Inc | 0.38% | 88.1% |
| 97 | INBXInhibrx Biosciences Inc | 0.35% | 88.4% |
| 98 | TSHATaysha Gene Therapies Inc | 0.35% | 88.8% |
| 99 | ARDXArdelyx Inc | 0.35% | 89.1% |
| 100 | AVTXAvalo Therapeutics Inc | 0.35% | 89.5% |
| 101 | MNKDMannKind Corp | 0.34% | 89.8% |
| 102 | ANNXAnnexon Inc | 0.33% | 90.2% |
| 103 | ORICORIC Pharmaceuticals Inc | 0.33% | 90.5% |
| 104 | ZBIOZenas Biopharma Inc | 0.32% | 90.8% |
| 105 | JBIOJade Biosciences Inc | 0.32% | 91.1% |
| 106 | KURAKura Oncology Inc | 0.32% | 91.4% |
| 107 | OLMAOlema Pharmaceuticals Inc | 0.32% | 91.8% |
| 108 | CDNACareDx Inc | 0.30% | 92.1% |
| 109 | BCAXBicara Therapeutics Inc | 0.30% | 92.4% |
| 110 | VORVor BioPharma Inc | 0.30% | 92.7% |
| 111 | XNCRXencor Inc | 0.29% | 93.0% |
| 112 | AVBPArriVent Biopharma Inc | 0.28% | 93.2% |
| 113 | REPLReplimune Group Inc | 0.28% | 93.5% |
| 114 | CTMXCytomX Therapeutics Inc | 0.28% | 93.8% |
| 115 | JANXJanux Therapeutics Inc | 0.28% | 94.1% |
| 116 | SIONSionna Therapeutics Inc | 0.27% | 94.3% |
| 117 | GERNGeron Corp | 0.26% | 94.6% |
| 118 | SLDBSolid Biosciences Inc | 0.24% | 94.8% |
| 119 | RIGLRigel Pharmaceuticals Inc | 0.24% | 95.1% |
| 120 | ALLOAllogene Therapeutics Inc | 0.24% | 95.3% |
| 121 | SANASana Biotechnology Inc | 0.23% | 95.5% |
| 122 | ALTAltimmune Inc | 0.23% | 95.8% |
| 123 | RGNXREGENXBIO Inc | 0.22% | 96.0% |
| 124 | IRWDIronwood Pharmaceuticals Inc | 0.22% | 96.2% |
| 125 | IMMXImmix Biopharma Inc | 0.20% | 96.4% |
| 126 | FDMT4D Molecular Therapeutics Inc | 0.20% | 96.6% |
| 127 | OCGNOcugen Inc | 0.20% | 96.8% |
| 128 | CADLCandel Therapeutics Inc | 0.19% | 97.0% |
| 129 | SVRASavara Inc | 0.18% | 97.2% |
| 130 | PRMEPrime Medicine Inc | 0.18% | 97.4% |
| 131 | TRAXFirst Tracks Biotherapeutics Inc | 0.17% | 97.5% |
| 132 | DMRADamora Therapeutics Inc | 0.17% | 97.7% |
| 133 | SPRYARS Pharmaceuticals Inc | 0.17% | 97.9% |
| 134 | MPLTMapLight Therapeutics Inc | 0.17% | 98.1% |
| 135 | ABUSArbutus Biopharma Corp | 0.16% | 98.2% |
| 136 | MYGNMyriad Genetics Inc | 0.16% | 98.4% |
| 137 | CABACabaletta Bio Inc | 0.15% | 98.5% |
| 138 | CMPXCompass Therapeutics Inc | 0.14% | 98.7% |
| 139 | EBSEmergent BioSolutions Inc | 0.13% | 98.8% |
| 140 | PRTAProthena Corp PLC | 0.13% | 98.9% |
| 141 | VNDAVanda Pharmaceuticals Inc | 0.13% | 99.1% |
| 142 | CATXPerspective Therapeutics Inc | 0.13% | 99.2% |
| 143 | OVIDOvid therapeutics Inc | 0.12% | 99.3% |
| 144 | VSTMVerastem Inc | 0.12% | 99.4% |
| 145 | MDXGMiMedx Group Inc | 0.11% | 99.5% |
| 146 | LXEOLexeo Therapeutics Inc | 0.11% | 99.6% |
| 147 | ACHVAchieve Life Sciences Inc | 0.08% | 99.7% |
| 148 | SGMTSagimet Biosciences Inc | 0.07% | 99.8% |
| 149 | BBOTBridgeBio Oncology Therapeutics Inc | 0.06% | 99.9% |
What changed since the Mar 31, 2026 filing
Entered the reported positions
Left the reported positions
Entered means the name is among the reported top positions now and was not in the previous filing. That can be a purchase or a rise in weight, and the filing does not say which.
Funds that hold the most of the same stocks
The share of XBI that is also in each fund, from the positions both report. Open a fund for its own page, or the overlap figure to compare the two.
| Fund | Overlap | Shared |
|---|---|---|
| LABUDirexion Daily S&P Biotech Bull 3X Shares | 66.9% | 147 |
| IBBiShares Biotechnology ETF | 41.6% | 122 |
| IWOiShares Russell 2000 Growth ETF | 14.1% | 102 |
| VHTVANGUARD HEALTH CARE INDEX FUND | 12.9% | 124 |
| IYHiShares U.S. Healthcare ETF | 10.4% | 24 |
| VBKVANGUARD SMALL-CAP GROWTH INDEX FUND | 10.3% | 43 |
| ARKGARK Genomic Revolution ETF | 9.8% | 12 |
| IWMiShares Russell 2000 ETF | 9.4% | 123 |
Questions people ask
What are the top holdings of XBI?
Its filing lists 149 stock positions. The largest are APOGEE THERAPEUTICS INC 1.5%, MRNA 1.4%, TWST 1.4%, and the ten largest together are 13.3% of the fund. The full list with weights is on this page.
How many stocks are in XBI?
XBI reports 149 stock positions in its SEC filing of Jun 30, 2026, and together they are 100% of the fund. Cash, futures and bonds the fund holds are not counted.
How do I check whether XBI holds a particular stock?
Search the full list on this page by ticker or company name, for example NVDA or Nvidia. A stock the fund holds shows with its weight and its rank in the fund. If it does not show, the fund did not report it as a position in this filing.
How often do these holdings change?
Funds report their positions to the SEC at each quarter end, and the SEC publishes the filing about 60 days later. Ploutos reads the latest one every week, so the page changes four times a year, and shows the date of the filing it reads.
Why does the coverage not reach 100%?
The list is the stock positions the fund reports. Cash, futures, bonds and other assets the filing carries are not listed, and what the stocks add up to is the coverage shown. A stock fund lands near 100; a fund that holds futures or a cash sleeve lands lower. Weights are of the whole fund.
Compare XBI with another fund·All fund pairs
Descriptive data from public SEC filings. Nothing on this page is a recommendation to buy, sell or hold any fund or stock, and holdings change between filings.